Affiliation:
1. Department of Infectious Diseases and Hepatology, Medical University of Lodz, Kniaziewicza 1/5, 91-347 Łódź, Poland
Abstract
Objectives: The aim of this study was to compare the prevalence and characteristics of HIV late presenters (LPs) and advanced LPs (aLPs) registered in the Lodz HIV centre during the COVID-19 pandemic (2020–2021) with those of the pre-pandemic period (2017–2019). Methods: A retrospective analysis was performed of the predictive factors associated with HIV LPs and aLPs based on multivariable logistic regression. The patient entry into specialist HIV care after diagnosis during the pandemic was analysed. Results: Of 121 newly diagnosed HIV infections during the pandemic, 49.6% had late presentation and 36.4% had advanced HIV disease (AHD). In the pre-pandemic period, out of 154 newly diagnosed patients, 58.4% were LPs and 38.3% were aLPs. Independent risk factors for HIV late presentation were older age (OR: 1.04, 95% CI: 1.01–1.076; p = 0.008), diagnosis in hospital (OR: 5.63, 95% CI: 2.87–11.05; p < 0.001) and negative VDRL as compared to positive VDRL (OR: 2.48, 95% CI: 1.19–5.15; p = 0.015). The same predictive factors were associated with aLPs: older age (OR: 1.07, 95% Cl 1.04–1.11; p < 0.001), HIV diagnosis in hospital (OR: 4.25, 95% CI 2.17–8.29; p < 0.001) and negative VDRL as compared to positive VDRL (OR: 4.95, 95% CI 1.87–13.10; p = 0.001). HIV diagnosis during the pandemic was not a risk factor for late presentation nor for advanced late presentation. However, the time between HIV diagnosis and the first visit to an HIV centre was statistically lower in the pre-pandemic period (p = 0.0048); the median lengths of time between the date of HIV testing, the first visit to the centre and the initiation of ART did not differ between these two periods in LPs and aLPs (p > 0.05). Conclusions: The COVID-19 pandemic did not change the prevalence or characteristics of late presentation and aLPs among newly diagnosed patients, nor did it extend the time to enrolment in HIV care or ART introduction in these groups.
Reference27 articles.
1. HIV care in times of the COVID-19 crisis—Where are we now in Central and Eastern Europe?;Kowalska;Int. J. Infect. Dis.,2020
2. Impact of the COVID-19 pandemic situation on HIV care in Liège, Belgium;Lambert;HIV Res. Clin. Pract.,2021
3. EuroTEST COVID-19 impact assessment consortium of partners. Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020;Stengaard;Eurosurveillance,2020
4. INSIGHT START Study Group, Lundgren, J.D., Babiker, A.G., Gordin, F., Emery, S., and Grund, B. (2015). Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N. Engl. J. Med., 27, 795–807.
5. Smit, C., Hallett, T.B., Lange, J., Garnett, G., and de Wolf, F. (2008). Late entry to HIV care limits the impact of antiretroviral therapy in The Netherlands. PLoS ONE, 3.